<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450775</url>
  </required_header>
  <id_info>
    <org_study_id>5299</org_study_id>
    <nct_id>NCT00450775</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars</brief_title>
  <official_title>Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q&#xD;
      for the prevention and treatment of scarring.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>1 yr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient acceptance</measure>
    <time_frame>1 yr</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dermatix Q</intervention_name>
    <description>Dermatix Q applied twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patients at least 18 years of age&#xD;
&#xD;
          -  Patients who are at serious risk of hypertrophic scarring (due to family history,&#xD;
             race, recent surgery, etc)&#xD;
&#xD;
          -  Able and willing to provide informed consent and likely to complete all study visits&#xD;
&#xD;
          -  All Fitzpatrick skin types will be evaluated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known contraindications to Dermatix or any of its components&#xD;
&#xD;
          -  Age of scar is &gt; 4 months&#xD;
&#xD;
          -  Keloid scars (scars with increased fibroblastic activity that has exceeded the&#xD;
             boundaries of the original scar)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dadeland Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dadeland Dermatology</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>September 23, 2008</last_update_submitted>
  <last_update_submitted_qc>September 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>David Rodriguez, MD</name_title>
    <organization>Dadeland Dermatology</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

